% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:1024635,
      author       = {Galldiks, Norbert},
      title        = {{D}iagnosing pseudoprogression in glioblastoma: {A}
                      challenging clinical issue},
      journal      = {Neuro-oncology practice},
      volume       = {11},
      number       = {1},
      issn         = {2054-2577},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2024-02308},
      pages        = {1 - 2},
      year         = {2024},
      abstract     = {Pseudoprogression refers to the transient worsening of
                      radiographic features on anatomical MRI after glioblastoma
                      treatment, especially following radiotherapy combined with
                      alkylating agents. This phenomenon mimics tumor progression,
                      leading to misinterpretation and potentially premature
                      adjustments to the ongoing treatment. Importantly,
                      consequences of misinterpreting pseudoprogression may be
                      profound. Patients may be subjected to unnecessary changes
                      in treatment, including premature discontinuation of
                      therapies that could potentially be beneficial or to
                      overestimation of the efficacy of the subsequent therapy.
                      Moreover, the emotional burden on patients and their
                      families cannot be overstated.Distinguishing between actual
                      tumor progression and pseudoprogression remains clinically
                      challenging. More accurate diagnostic tools, such as
                      positron emission tomography using radiolabeled amino
                      acids1–3 and advanced MRI such as perfusion-weighted
                      imaging,4 may add valuable additional diagnostic information
                      in a considerable fraction of patients.In the study by
                      Blakstad and colleagues recently published in Neuro-Oncology
                      Practice,5 284 glioblastoma patients who underwent
                      radiotherapy $(100\%)$ with concomitant $(95\%)$ and
                      adjuvant temozolomide chemotherapy over ≤6 cycles $(92\%)$
                      and subsequent MRI follow-up scans were evaluated regarding
                      the incidence and clinical significance of pseudoprogression
                      using the Response Assessment in Neuro-Oncology Working
                      Group criteria.6 Confirmation MRI scans during follow-up
                      were used to verify the initial MRI findings post-radiation
                      allowing, for example, the reclassification from progressive
                      disease to pseudoprogression when follow-up MRI changes
                      stabilized or regressed without change in treatmen},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {38222056},
      UT           = {WOS:001134503500001},
      doi          = {10.1093/nop/npad078},
      url          = {https://juser.fz-juelich.de/record/1024635},
}